QUELL THERAPEUTICS LIMITED

Active London

Research and experimental development on biotechnology

146 employees website.com
Life sciences and medical technology Research and experimental development on biotechnology
Q

QUELL THERAPEUTICS LIMITED

Research and experimental development on biotechnology

Founded 19 Mar 2019 Active London, England 146 employees website.com
Life sciences and medical technology Research and experimental development on biotechnology
Accounts Submitted 23 Jul 2025 Next due 30 Sept 2026 5 months remaining
Confirmation
Net assets £79M £4M 2024 year on year
Total assets £91M £37M 2024 year on year
Total Liabilities £12M £33M 2024 year on year
Charges None No charges registered

Contact & Details

Contact

Registered Address

3rd Floor, Translation & Innovation Hub 84 Wood Lane London W12 0BZ England

Telephone

0800 000 0000

Email

info@example.com

Website

www.example.com

Full company profile for QUELL THERAPEUTICS LIMITED (11890040), an active life sciences and medical technology company based in London, England. Incorporated 19 Mar 2019. Research and experimental development on biotechnology. View financials, directors, shareholders, and filings.

Business Summary

This company specializes in providing innovative solutions and services across multiple sectors.

Products & Services

consulting software analytics integration

Reports

Credit Report

In-depth credit score, financial analysis, risk assessment and company intelligence.

Financials

Financials

Period 1 Jan → 31 Dec 2024
Type Total Exemption Full
Next accounts 31 December 2025
Due by 30 September 2026 9 months

Balance Sheet & P&L (2019–2024)

Cash in Bank

£60.47M

Decreased by £46.25M (-43%)

Net Assets

£78.59M

Decreased by £3.85M (-5%)

Total Liabilities

£12.18M

Decreased by £32.94M (-73%)

Turnover

£43.83M

Increased by £34.67M (+378%)

Employees

146

Increased by 8 (+6%)

Debt Ratio

13%

Decreased by 22 (-63%)

Financial History

Revenue, profit, EBITDA and key financial figures

2024
Dec Year End
2023
Dec Year End
P&L
Revenue
£142.3M
£128.7M
Gross Profit
£48.2M
£43.1M
Operating Profit
£22.4M
£19.8M
Net Profit
£18.1M
£15.9M
EBITDA
£31.5M
£28.2M
Assets
Cash
£24.7M
£21.3M
Total Assets
£89.4M
£82.1M
Liabilities
Total Liabilities
£45.2M
£41.8M
Key Metrics
Employees
1,247
1,156
Latest Revenue
£142.3M
Latest EBITDA
£31.5M
Cash Position
£24.7M

Funding

Fundraising & Grants

Funding Rounds 4

Investors (12)

Investor NameInvestor SinceParticipating Rounds
Investor 2May 2019Series A
Investor 3May 2019Series A, Series B
Investor 1Feb 2021Series A

Share Capital

Share Capital

Share allotments and capital structure

8 Allotments 63,524,050 Shares £87.89m Total
Date FromShare ClassShares AllottedAmount RaisedPrice/Share
2 Jun 202312,025,012£19.88m£1.654
25 Mar 202223,232,316£43.91m£1.89
4 Dec 202015,600,000£15.60m£1
19 Aug 2020146,341£1.463£0
19 Aug 2020146,341£1.463£0

Officers

Officers

1 active 2 resigned
Status
Tyrell Jermaine RiversDirectorAmericanUnited States532 Jun 2023Active

Shareholders

Shareholders (109)

Syncona Portfolio Limited
30.0%
45,171,429
Jeito S.l.p
10.5%
15,873,015

Persons with Significant Control

Persons with Significant Control (1)

1 Active 1 Ceased

Syncona Limited

British Channel Islands

Active
Notified 29 Mar 2019
Nature of Control
  • Ownership Of Shares 25 To 50 Percent,voting Rights 25 To 50 Percent

Syncona Portfolio Limited

Ceased 29 Mar 2019

Ceased

Group Structure

Group Structure

QUELL THERAPEUTICS LIMITED Current Company

Charges

Charges

No charges registered

Properties

Properties

1 leasehold 1 total
AddressTenurePrice PaidDate Added
Translation And Innovation Hub, White City Campus, 80 Wood Lane, London (W12 0BZ) HAMMERSMITH AND FULHAM
Leasehold-27 Aug 2024
Translation And Innovation Hub, White City Campus, 80 Wood Lane, London (W12 0BZ)
Leasehold
Added 27 Aug 2024
District HAMMERSMITH AND FULHAM

Documents

Company Filings

DateCategoryDescriptionDocument
15 Dec 2025CapitalCapital Cancellation Shares
15 Dec 2025CapitalCapital Return Purchase Own Shares
15 Dec 2025CapitalCapital Return Purchase Own Shares
19 Nov 2025CapitalCapital Cancellation Shares
1 Oct 2025CapitalCapital Name Of Class Of Shares
15 Dec 2025 Capital

Capital Cancellation Shares

15 Dec 2025 Capital

Capital Return Purchase Own Shares

15 Dec 2025 Capital

Capital Return Purchase Own Shares

19 Nov 2025 Capital

Capital Cancellation Shares

1 Oct 2025 Capital

Capital Name Of Class Of Shares

Recent Activity

Latest Activity

Capital Cancellation Shares

4 months ago on 15 Dec 2025

Capital Return Purchase Own Shares

4 months ago on 15 Dec 2025

Capital Return Purchase Own Shares

4 months ago on 15 Dec 2025

Capital Cancellation Shares

5 months ago on 19 Nov 2025

Capital Name Of Class Of Shares

6 months ago on 1 Oct 2025